<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2020-05-05</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2221</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction</article-title><trans-title-group xml:lang="ru"><trans-title>Динамика сосудистой жесткости и эндотелиальной функции при комбинированном лечении сердечной недостаточности с сохраненной фракцией выброса</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахильгова</surname><given-names>З. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhilgova</surname><given-names>Z. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ахильгова Зарина Макшариповна - аспирант, кафедра терапии и подростковой медицины, РМАНПО.</p><p>125993, Москва, ул. Баррикадная, 2/1.</p></bio><bio xml:lang="en"><p>Zarina M. Akhilgova - MD, Post-Graduated Student, Chair of Therapy and Teenage Medicine, Russian Medical Academy of Continuous Professional Education.</p><p>Barrikadnaya ul. 2/1, Moscow, 123993.</p></bio><email xlink:type="simple">zarina.akhilgova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алмазова</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Almazova</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алмазова Ильда Исмаиловна – кандидат медицинских наук, ассистент, кафедра терапии и подростковой медицины, РМАНПО.</p><p>125993, Москва, ул. Баррикадная, 2/1.</p></bio><bio xml:lang="en"><p>Ilda I. Almazova - MD, PhD, Assistant, Chair of Therapy and Teenage Medicine, Russian Medical Academy of Continuous Professional Education.</p><p>Barrikadnaya ul. 2/1, Moscow, 123993.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Габитова</surname><given-names>Н. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Gabitova</surname><given-names>N. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Габитова Надежда Хасановна - кандидат медицинских наук, заведующая 11-м кардиологическим отделением, ГКБ им. В.В. Вересаева.</p><p>127411, Москва, ул. Лобненская, 10.</p></bio><bio xml:lang="en"><p>Nadezhda Kh. Gabitova - MD, PhD, Head of Cardiology Department №11, City Clinical Hospital named after V.V. Veresaev.</p><p>Lobnenskaya ul. 10, Moscow, 127411.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котаева</surname><given-names>Е. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotaeva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Котаева Елена Александровна - кандидат медицинских наук, заведующая 5-м кардиологическим отделением, ГКБ им. С.П. Боткина.</p><p>125284, Москва, 2-й Боткинский пр-д, 5. </p></bio><bio xml:lang="en"><p>Elena A. Kotaeva - MD, PhD, Head of Cardiology Department №5, City Clinical Hospital named after S.P. Botkin.</p><p>Botkinskiy pr-d 5, Moscow, 125284.</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Автандилов</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Avtandilov</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Автандилов Александр Георгиевич - доктор медицинских наук, профессор, заведующий кафедрой терапии и подростковой медицины, РМАНПО.</p><p>125993, Москва, ул. Баррикадная, 2/1.</p></bio><bio xml:lang="en"><p>Alexander G. Avtandilov - MD, PhD, Professor, Head of Chair of Therapy and Teenage Medicine, Russian Medical Academy of Continuous Professional Education.</p><p>Barrikadnayaul. 2/1, Moscow, 123993.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российская медицинская академия непрерывного профессионального образования</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская клиническая больница им. В.В. Вересаева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital named after V.V. Veresaev</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Городская клиническая больница им. С.П. Боткина</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital named after S.P. Botkin</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>03</day><month>07</month><year>2020</year></pub-date><volume>16</volume><issue>3</issue><fpage>377</fpage><lpage>382</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Akhilgova Z.M., Almazova I.I., Gabitova N.K., Kotaeva E.A., Avtandilov A.G., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Ахильгова З.М., Алмазова И.И., Габитова Н.Х., Котаева Е.A., Автандилов А.Г.</copyright-holder><copyright-holder xml:lang="en">Akhilgova Z.M., Almazova I.I., Gabitova N.K., Kotaeva E.A., Avtandilov A.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2221">https://www.rpcardio.online/jour/article/view/2221</self-uri><abstract><sec><title>Aim</title><p>Aim. To assess the effect of combination therapy (perindopril, indapamide, amlodipine) on vascular stiffness and endothelial function in patients with heart failure with preserved ejection fraction (HFpEF).</p></sec><sec><title>Material and methods</title><p>Material and methods. Patients with HFpEF (n=30) were included in a nonrandomized, uncontrolled trial. All patients had a comprehensive examination: a six-minute walk test to determine exercise tolerance, echocardiography, determination of the diameter of the brachial artery with an assessment of its endothelium-dependent vasodilation (EDVD). Photoplethysmography and compression oscillometry were also carried out to assess the stiffness characteristics of vessels of various calibers and the determination of the cardio-ankle vascular index. Patients were examined initially and 16 weeks after the combination therapy order (perindopril 10 mg/day, indapamide 2.5 mg/day, amlodipine 5 mg/day).</p></sec><sec><title>Results</title><p>Results. The data obtained during therapy shows improvement of the endothelial function for all patients: the initial EDVD was 8.5%, by the end of the observation period it increased to 11.4% (p=0.007). A significant decrease in the systemic vascular resistance from 2591 dyn*cm-5 to 2380 dyn*cm-5 (p=0.03) and in the level of specific peripheral resistance from 32.9 dyn/sec/cm-5 to 28.5 dyn/sec/cm-5 (p=0.0051). The stiffness indices of small resistive vessels also decreased: vascular stiffness index from 10.2±2.2 m/sec to 8.4±2.5 m/sec (p&lt;0.0001) and pulse wave reflection index from 70.2±13.5% to 61.9±14.7% (p=0.0011). Cardio-ankle vascular index (CAVI) initially amounted to 9.2±1.3 and decreased by the end of the observation period during treatment to 8.3±1.1 (p=0.0003). The pulse blood pressure was significantly decrease from 71.31±15.5 mm Hg to 64.5±12.9 mm Hg (p=0.0048) and there was a tendency to decrease in pulse wave velocity from 808 cm/sec to 730 cm/sec.</p></sec><sec><title>Conclusion</title><p>Conclusion. The results of the study showed a statistically significant improvement in the elastic component of small resistive and major vessels, the endothelial function. The obtained results prove a decrease in the stiffness characteristics of blood vessels during the combination therapy.</p><p>This suggests that the combination of drugs with a different mechanism of action improves not only the state of the endothelium and its function, but also significantly reduces the stiffness of the great vessels, restores the microcirculatory support of the interstitium of the myocardium and vascular wall in patients with HFpEF and leads to an improvement in the clinical status of patients with this syndrome.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Оценить влияние комбинированной терапии (периндоприл, индапамид, амлодипин) на жесткость стенки сосудов и эндотелиальную функцию у пациентов с сердечной недостаточностью с сохраненной фракцией выброса (СНсФВ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В нерандомизированном неконтролируемом исследовании приняли участие 33 пациента, которым проводилось комплексное обследование: тест с шестиминутной ходьбой для определения толерантности к физическим нагрузкам, эхокардиография, определение диаметра плечевой артерии с оценкой ее эндотелий-зависимой вазодилатации (ЭЗВД). Также проводилась фотоплетизмография и компрессионная осциллометрия для оценки жесткостных характеристик сосудов разного калибра и определение сердечно-лодыжечного сосудистого индекса. Пациенты обследовались исходно и через 16 нед после назначения комбинированной терапии (периндоприл 10 мг/сут, индапамид 2,5 мг/сут, амлодипин 5 мг/сут).</p></sec><sec><title>Результаты</title><p>Результаты. За время наблюдения у всех пациентов улучшилась эндотелиальная функция: увеличилась ЭЗВД (с 8,5% до 11,4%; р=0,007). Отмечено снижение общего периферического сопротивления (с 2591 до 2380 дин*см-5; р=0,03), уровня удельного периферического сопротивления (с 32,9 до 28,5 дин/с/см-5; р=0,0051), индексов жесткости мелких резистивных сосудов: индекса жесткости сосудов (c 10,2±2,2 до 8,4±2,5 м/с; р&lt;0,0001) и индекса отражения пульсовой волны (с 70,2±13,5% до 61,9±14,7%; р=0,0011), а также сердечно-лодыжечного сосудистого индекса (с 9,2±1,3 до 8,3±1,1; р=0,0003), пульсового артериального давления (с 71,31±15,5 до 64,5±12,9 мм рт.ст.; р=0,0048). Также отмечена тенденция к снижению скорости пульсовой волны (с 808 см/сек до 730 см/сек).</p></sec><sec><title>Заключение</title><p>Заключение. Результаты проведенного исследования показали статистически значимое улучшение эластического компонента мелких резистивных и магистральных сосудов, восстановление функции эндотелия. Полученные результаты доказывают снижение характеристик жесткости сосудов на фоне комбинированного лечения. Это свидетельствует о том, что комбинация препаратов, имеющих разный механизм действия, улучшает не только состояние эндотелия и его функции, но и заметно снижает жесткость магистральных сосудов, восстанавливает микроциркуляторное обеспечение интерстиция миокарда и сосудистой стенки при СНсФВ и приводит к улучшению клинического статуса больных с данным синдромом.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечная недостаточность с сохраненной фракцией выброса</kwd><kwd>лечение</kwd><kwd>жесткость сосудистой стенки</kwd><kwd>эндотелиальная функция</kwd><kwd>микроциркуляция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure with preserved ejection fraction</kwd><kwd>treatment</kwd><kwd>vascular wall stiffness</kwd><kwd>endothelial function</kwd><kwd>microcirculation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dunlay S. M., Roger V.L., Redfield M.M. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591-602. DOI:10.1038/nrcardio.2017.65.</mixed-citation><mixed-citation xml:lang="en">Dunlay S. M., Roger V.L., Redfield M.M. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591-602. DOI:10.1038/nrcardio.2017.65.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Levy B.I. How to Explain the Differences Between Renin Angiotensin System Modulators. Am J Hyper-tens. 2005;18(9 Pt 2):134S-141S. DOI:10.1016/j.amjhyper.2005.05.005.</mixed-citation><mixed-citation xml:lang="en">Levy B.I. How to Explain the Differences Between Renin Angiotensin System Modulators. Am J Hyper-tens. 2005;18(9 Pt 2):134S-141S. DOI:10.1016/j.amjhyper.2005.05.005.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Upadhya B., Taffet G.E., Cheng C.P., Kitzman D.W. Heart Failure with Preserved Ejection Fraction in the Elderly: Scope of the Problem. J Mol Cell Cardiol. 2015;83:73-87.. DOI:10.1016/j.yjmcc.2015.02.025.</mixed-citation><mixed-citation xml:lang="en">Upadhya B., Taffet G.E., Cheng C.P., Kitzman D.W. Heart Failure with Preserved Ejection Fraction in the Elderly: Scope of the Problem. J Mol Cell Cardiol. 2015;83:73-87.. DOI:10.1016/j.yjmcc.2015.02.025.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammed S.F., Hussain S., Mirzoyev S.A., et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550-9. DOI:10.1161/circulationaha.114.009625.</mixed-citation><mixed-citation xml:lang="en">Mohammed S.F., Hussain S., Mirzoyev S.A., et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550-9. DOI:10.1161/circulationaha.114.009625.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Crea F., Merz N. B., Beltrame J. F., et al. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur Heart J. 2017;38(7):473-7. DOI:10.1093/eur-heartj/ehw461.</mixed-citation><mixed-citation xml:lang="en">Crea F., Merz N. B., Beltrame J. F., et al. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur Heart J. 2017;38(7):473-7. DOI:10.1093/eur-heartj/ehw461.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gevaert A.B., Boen Jente R.A., et al. Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. Front Physiol. 2019;10:638. DOI:10.3389/fphys.2019.00638.</mixed-citation><mixed-citation xml:lang="en">Gevaert A.B., Boen Jente R.A., et al. Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. Front Physiol. 2019;10:638. DOI:10.3389/fphys.2019.00638.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kendall R.T., Feghali-Bostwick C.A. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:123. DOI:10.3389/fphar.2014.00123.</mixed-citation><mixed-citation xml:lang="en">Kendall R.T., Feghali-Bostwick C.A. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:123. DOI:10.3389/fphar.2014.00123.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC 2016. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128.</mixed-citation><mixed-citation xml:lang="en">ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC 2016. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Massie B.M., Carson P.E., M.D., McMurray J.J., et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med. 2008;359:2456-67. DOI:10.1056/NEJMoa0805450.</mixed-citation><mixed-citation xml:lang="en">Massie B.M., Carson P.E., M.D., McMurray J.J., et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med. 2008;359:2456-67. DOI:10.1056/NEJMoa0805450.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-6.</mixed-citation><mixed-citation xml:lang="en">Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Yip G., Wang M., Wang T., et. al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94:573-80. DOI:10.1136/hrt.2007.117978.</mixed-citation><mixed-citation xml:lang="en">Yip G., Wang M., Wang T., et. al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94:573-80. DOI:10.1136/hrt.2007.117978.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ахильгова З.М., Куркина М.В., Джиоева З.Р, и др. Диагностика и спорные вопросы лечения сердечной недостаточности с сохраненной фракцией выброса. Кардиосоматика. 2018; 4:32-7.</mixed-citation><mixed-citation xml:lang="en">Akhilgova Z.M., Kurkina M.V., Dzhioeva Z.R., et al. Diagnosis and the debatable issues of the treatment of heart failure with preserved ejection fraction. Cardiosomatics 2018;4:32-37 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">De Ciuceis C., Salvetti M., Paini A., et al. Comparison of lercanidipine plus hydrochlorothiazide vs. lercanidipine plus enalapril on micro and macrocirculation in patients with mild essential hypertension. Intern Emerg Med. 2017;12(7):963-74. DOI:10.1007/s11739-017-1696-7.</mixed-citation><mixed-citation xml:lang="en">De Ciuceis C., Salvetti M., Paini A., et al. Comparison of lercanidipine plus hydrochlorothiazide vs. lercanidipine plus enalapril on micro and macrocirculation in patients with mild essential hypertension. Intern Emerg Med. 2017;12(7):963-74. DOI:10.1007/s11739-017-1696-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ganado P., Ruiz E., M. Del Rio et al. Growth inhibitory activity of indapamide on vascular smooth muscle cells. European Journal of Pharmacology. 2001;428(1):19-27. DOI:10.1016/S0014-2999(01)01275-4.</mixed-citation><mixed-citation xml:lang="en">Ganado P., Ruiz E., M. Del Rio et al. Growth inhibitory activity of indapamide on vascular smooth muscle cells. European Journal of Pharmacology. 2001;428(1):19-27. DOI:10.1016/S0014-2999(01)01275-4.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Janie М., Lunder М., Sabovic М. Arterial Stiffness and Cardiovascular Tcerapy. Biomed Res Int. 2014;2014:621437. DOI:10.1155/2014/621437.</mixed-citation><mixed-citation xml:lang="en">Janie М., Lunder М., Sabovic М. Arterial Stiffness and Cardiovascular Tcerapy. Biomed Res Int. 2014;2014:621437. DOI:10.1155/2014/621437.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25. DOI:10.1161/CIRCULATIONAHA.105.595496.</mixed-citation><mixed-citation xml:lang="en">Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25. DOI:10.1161/CIRCULATIONAHA.105.595496.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ferguson J.M., Minas J., Siapantas S., et al. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. Journal of Cardiovascular Pharmacology. 2008;51(6):590-95. DOI:10.1097/FJC.0b013e31817a8316.</mixed-citation><mixed-citation xml:lang="en">Ferguson J.M., Minas J., Siapantas S., et al. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. Journal of Cardiovascular Pharmacology. 2008;51(6):590-95. DOI:10.1097/FJC.0b013e31817a8316.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Shahin Y., Khan J.A., Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012;221(1):18-33. DOI:10.1016/j.atherosclerosis.2011.12.005.</mixed-citation><mixed-citation xml:lang="en">Shahin Y., Khan J.A., Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012;221(1):18-33. DOI:10.1016/j.atherosclerosis.2011.12.005.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kengne A.P., Czernichow S., Huxley R. et al. Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 2009;54(2):399-404. DOI:10.1161/HYPERTENSIONAHA.109.133041.</mixed-citation><mixed-citation xml:lang="en">Kengne A.P., Czernichow S., Huxley R. et al. Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 2009;54(2):399-404. DOI:10.1161/HYPERTENSIONAHA.109.133041.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
